Legal & General Group
PRME icon

Legal & General Group’s Prime Medicine PRME Stock Holding History

Legal & General Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Sell
66,444
-14,305
-18% -$54.4K ﹤0.01% 2514
2025
Q4 		$280K Buy
80,749
+73,998
+1,096% +$329K ﹤0.01% 2538
2025
Q3 		$37.4K Buy
6,751
+1,852
+38% +$7.52K ﹤0.01% 2807
2025
Q2 		$12.1K Sell
4,899
-1,016
-17% -$1.57K ﹤0.01% 3216
2025
Q1 		$11.8K Sell
5,915
-364
-6% -$929 ﹤0.01% 3120
2024
Q4 		$18.4K Hold
6,279
– – ﹤0.01% 3051
2024
Q3 		$24.3K Hold
6,279
– – ﹤0.01% 2972
2024
Q2 		$32.3K Buy
6,279
+1,943
+45% +$11.8K ﹤0.01% 2865
2024
Q1 		$30.3K Hold
4,336
– – ﹤0.01% 2854
2023
Q4 		$38.4K Sell
4,336
-188
-4% -$1.45K ﹤0.01% 2844
2023
Q3 		$43.1K Sell
4,524
-267
-6% -$3.47K ﹤0.01% 2884
2023
Q2 		$70.2K Buy
4,791
+1,364
+40% +$19K ﹤0.01% 2847
2023
Q1 		$42.2K Buy
3,427
+2,502
+270% +$40.8K ﹤0.01% 2903
2022
Q4 		$17.1K Buy
+925
New +$16.7K ﹤0.01% 3188

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Legal & General Group's PRME Position: Q1 2026 in Review

Legal & General Group reduced its Prime Medicine (PRME) stake by 18% in Q1 2026, selling an estimated $54.4K and leaving 66,444 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #2514.

Legal & General Group first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $280K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Legal & General Group held 66,444 shares of Prime Medicine worth $231K as of Q1 2026.
  • Legal & General Group sold 14,305 Prime Medicine shares in Q1 2026, an estimated $54.4K.
  • Prime Medicine made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2514 holding.
  • Legal & General Group first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Legal & General Group's Prime Medicine position peaked at $280K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.